
    
      The study comprised 2-treatment period. Treatment Period 1 was a 52-week, double-blind
      treatment period in which QAW039 450 mg or 150 mg or placebo was added to standard-of-care
      asthma therapy according to GINA guidelines. Treatment Period 2 was an optional 104-week,
      single-blind treatment period in which patients received QAW039 450 mg or 150 mg or placebo
      added to standard-of-care asthma therapy according to GINA guidelines.
    
  